The “life-saving” Covid-19 treatment given when Donald Trump was seriously ill will be rolled out to vulnerable patients with the NHS next week.
When he was hospitalized for the coronavirus last year, Donald Trump said antibody treatment was a “godly blessing.”
Ronapreve is a combination of two monoclonal antibodies used to treat inpatient Covid patients who do not develop an antibody response to Covid-19.
Initially, the drug is given to patients over the age of 50 who do not have antibodies to Covid-19, or patients between the ages of 12 and 49 who are considered immunodeficient.
This comes as a relief for people suffering from certain cancers or autoimmune diseases who are struggling to build an antibody response through either vaccine or exposure to the virus.
The government said it had secured sufficient drug supplies to administer it to eligible patients in all four countries starting next week.
“We are excited to save lives from next week,” said Health Minister Sajid Javid.
“The UK is a world leader, especially in the identification and deployment of COVID-19 life-saving drugs. We continue to be important in finding the best treatments available to save lives and protect the NHS. We will make various efforts. “
The antibody cocktail of Casilibimab and Imdebimab was approved for clinical use in the United Kingdom by the Medicines and Healthcare Products Regulatory Agency (MHRA) last month. Javid welcomed the drug as the first drug specifically designed to fight Covid-19 and said its approval was “great news.”
Study data showed that Ronapreb can be used to prevent infection, treat the symptoms of acute Covid-19, and reduce the chances of hospitalization.
The most vulnerable patients are prioritized because it is expensive. Antibody tests are first used to assess whether a patient is serum-negative, that is, whether the patient has accumulated sufficient Covid-19 antibodies.
Developed by pharmaceutical companies Regeneron and Roche, the drug, administered by infusion, acts as a lining for the respiratory system by binding to the viral spike proteins and preventing them from infecting cells in the body.
Paul McManus, Covid-19 Lead of Roche Products Ltd, said:
“We are grateful to the Vaccine Task Force and NHS England for working with Regeneron to help this important antibody cocktail help treat and prevent acute Covid-19 throughout the UK.”
The news of this drug arrives as a relief without further restrictions, as Sage warns of 2,000 to 7,000 Covid hospitalizations daily the following month.
Scientists have said that Ronapreb can significantly reduce the pressure on the NHS, depending on the amount of drug used.
Pennyward, a visiting professor of pharmaceutical medicine at King’s College London, said: As long as it is administered rapidly after exposure, it reduces potential infections and illnesses from close contact by approximately the same amount. “
“It’s a relief,” said Chris Seedsby, one of the estimated 500,000 immunocompromised people in the UK, when he learned that the drug was approved by MHRA. He has no immunological memory due to a rare disorder called Hyper IgM Syndrome.
Chris, 45, from Hertfordshire, said: This is not our free day yet, but it is a step in the right direction. You can finally start breathing again. “